1. Overproduction of very low-density lipoproteins in the hallmark of the dyslipi- demia in the metabolic syndrome;Adiels;Arterioscler Thromb Vasc Biol,2008
2. Beyond low-density lipoprotein: addressing the athero- genic lipid triad in type 2 diabetes mellitus and the metabolic syndrome;Nesto;Am J Cardiovasc Drugs,2005
3. Endothelial-vasoprotec- tive effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy;Sorrentino;Circulation,2010
4. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769–818.
5. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferonic P, Uva MS, Taskinen M-R, Tendera M, Tuomilehto J, Valensi P, Zamorano JL. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular disease of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013 0ct;34(39):3035–87.